Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Agios Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $58.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2.05% year-over-year to $58.0 million; the TTM value through Dec 2025 reached $58.0 million, up 2.05%, while the annual FY2025 figure was $58.0 million, 2.05% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $58.0 million in Q4 2025 per AGIO's latest filing, roughly flat from $57.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $69.5 million in Q1 2021 to a low of $54.6 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $57.3 million, with a median of $56.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): decreased 21.55% in 2022, then rose 2.48% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $60.4 million in 2021, then decreased by 9.36% to $54.8 million in 2022, then increased by 1.57% to $55.7 million in 2023, then grew by 2.08% to $56.8 million in 2024, then rose by 2.05% to $58.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Shares Outstanding (Weighted Average) are $58.0 million (Q4 2025), $57.8 million (Q3 2025), and $57.7 million (Q2 2025).